Samsung Bioepis files lawsuit against AbbVie over mega-selling RA drug Humira
South Korean drug developer Samsung Bioepis is mounting a legal challenge to patents held by US pharma AbbVie (NYSE: ABBV) on Humira (adalimumab) for rheumatoid arthritis – the world’s best-selling drug.
Samsung Bioepis, a joint venture between Korean conglomerate Samsung and US biotech company Biogen (Nasdaq: BIIB), confirmed on Monday that it had filed a lawsuit in the UK last month as it seeks to develop a biosimilar version of the drug.
The composition patent for Humira expires in October 2018 and AbbVie has submitted new patents in attempts to delay the entry of such biosimilars and protect its own product, a move Samsung Bioepis has objected to over its impact on market competition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze